共 50 条
- [21] Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag TrialBLOOD, 2023, 142Furstenau, MoritzGiza, AdamFink, Anna-MariaRobrecht, SandraWeiss, JonathanKleinert, FanniSchneider, ChristofTausch, EugenFischer, KirstenLangerbeins, PetraAl-Sawaf, OthmanSchetelig, JohannesDreger, PeterBoettcher, SebastianKreuzer, Karl-AntonRitgen, MatthiasSchilhabel, AnkeBrueggemann, MonikaStilgenbauer, StephanEichhorst, Barbara F.Hallek, MichaelCramer, Paula
- [22] Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisBLOOD ADVANCES, 2020, 4 (22) : 5773 - 5784Noy, Arielade Vos, SvenColeman, MortonMartin, PeterFlowers, Christopher R.Thieblemont, CatherineMorschhauser, FranckCollins, Graham P.Shuo, MaPeles, ShacharSmith, Stephen D.Barrientos, Jacqueline C.Chong, ElizabethWu, ShiquanCheung, Leo W-KKwei, KevinHauns, BernhardArango-Hisijara, IsraelChen, Robert
- [23] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD ResultsBLOOD, 2021, 138 : 3720 - +Jain, NitinKeating, Michael J.Thompson, Philip A.Ferrajoli, AlessandraBurger, Jan A.Borthakur, GautamTakahashi, KoichiEstrov, Zeev E.Sasaki, KojiKadia, Tapan M.Konopleva, MarinaAlvarado, YesidYilmaz, MusaDiNardo, Courtney D.Bose, PrithvirajOhanian, MaroPemmaraju, NaveenJabbour, Elias J.Kanagal-Shamanna, RashmiPatel, KeyurWang, WeiJorgensen, Jeffrey L.Wang, Sa A.Garg, NaveenWang, XuemeiWei, ChongjuanCruz, NicholeAyala, AnaPlunkett, WilliamKantarjian, HagopGandhi, VarshaWierda, William G.
- [24] Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 StudyBLOOD, 2021, 138 : 3754 - +Siddiqi, TanyaClay, PamelaMurray, KateShekh, NavshinaMuir, AlexandraRosen, Steven T.Coutre, Steven
- [25] Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLLCANCER RESEARCH, 2015, 75Coutre, StevenFurman, RichardFlinn, IanBurger, JanBlum, KristieSharman, JeffJones, JeffreyWierda, WilliamZhao, WeiqiangHeerema, NylaJohnson, AmyAnh TranZhou, CathyBilotti, ElizabethJames, DanelleByrd, JohnO'Brien, Susan
- [26] MINIMAL RESIDUAL DISEASE (MRD)-DRIVEN TREATMENT PERSONALIZATION WITH SEQUENTIAL ADDITION OF IBRUTINIB (IBR) TO VENETOCLAX (VEN) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPROVE STUDYHAEMATOLOGICA, 2021, 106 (10) : 4 - 4Scarfo, L.Heltai, S.Albi, E.Scarano, E.Schiattone, L.Farina, L.Gaidano, G.Deodato, M.Ferrario, A.Motta, M.Reda, G.Sancetta, R.Coscia, M.Ladetto, M.Laurenti, L.Varettoni, M.Perotta, E.Capasso, A.Ranghetti, P.Colia, M.Ghia, P.
- [27] Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemiaHEMASPHERE, 2025, 9 (01):Ryan, Christine E.Ren, YueTyekucheva, SvitlanaArnason, Jon E.Boruchov, Adam M.Jacobson, Caron A.Fisher, David C.Miskin, HariSportelli, PeterBrown, Jennifer R.Davids, Matthew S.
- [28] Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR StudyBLOOD, 2023, 142Hillmen, PeterCairns, David AllanBloor, Adrian John CliftonAllsup, DavidCwynarski, KatePettitt, AndrewPaneesha, ShankaranarayanaFox, Christopher P.Eyre, Toby A.Forconi, FrancescoElmusharaf, NagahKennedy, BenGribben, John G.Pemberton, NicholasSheehy, OonaghPreston, GavinSchuh, AnnaHoward, DenaHockaday, AnnaJackson, SharonGreatorex, NatashaGirvan, SeanBell, SueBrown, JuliaWebster, NicholaDalal, Suritade Tute, Ruth M.Rawstron, AndrewPatten, Piers E. M.Munir, Talha
- [30] Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrationsBMJ OPEN, 2020, 10 (10):Levin, Mark-DavidKater, ArnonMattsson, MattiasKersting, SabinaRanti, JuhaThi Tuyet Tran, HoaNasserinejad, KazemNiemann, Carsten Utoft